OLIG2 is a transcription factor that is critical for tumor initiation and growth. Curtana’s solution is to add an OLIG2 inhibitor to conventional therapy at the time of diagnosis.

Curtana’s clinical candidate, CT-179, is a highly potent and selective small molecule inhibitor of OLIG2 with excellent drug-like properties. The drug can be taken by mouth, administered once …

Feb 4, 2025 · OLIG2-expressing tumor stem cells have been shown to drive recurrence in Sonic Hedgehog (SHH)-subgroup medulloblastoma (MB) and patients urgently need specific …

Feb 4, 2025 · The research teams collaborated with U.S. drug company, Curtana Pharmaceuticals, that developed the experimental small molecule drug, termed CT-179. They …

By targeting OLIG2-expressing cancer stem cells, CT-179 addresses one of the primary challenges in treating SHH medulloblastoma—tumor recurrence. This innovative approach has …

Oct 7, 2020 · Curtana Pharmaceuticals, a privately-held, preclinical stage biopharmaceutical company, today announced that the Food and Drug Administration (FDA) has granted Rare …

Jun 16, 2021 · CT-179 is a highly potent and selective small molecule inhibitor of OLIG2, a transcription factor that is essential to normal early brain development but is not actively …

Aug 15, 2017 · Curtana is targeting Olig2, a transcription factor important to normal brain development that has been shown to be a critical oncogene controlling tumor initiation, growth, …

CT-179 is a novel small molecule OLIG2 inhibitor developed by Curtana Pharmaceuticals (molecular weight (MW) 397.3 g/mol, patent application WO2016138479A1) that has shown …

CT-179 ound in virtually all GBM cells that are positive for the tumorigenic CD133 cancer stem cell marker. Curtana’s lead clinical candidate, CT-179, is a highly potent inhibitor of Olig2 that …